MUM1／IRF4在滤泡性淋巴瘤中的表达及其临床病理意义  

MUM1/IRF4 expression in follicular lymphoma and its clinical and pathological significance

作　　者：邹霜梅[1] 应建明[1] 薛丽燕[1] 郑闪[1] 刘秀云[1] 温芃[1] 吕宁[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院肿瘤研究所病理科,北京100021

出　　处：《白血病．淋巴瘤》2011年第6期353-356,共4页Journal of Leukemia & Lymphoma

基　　金：基金项目：首都医学科技发展基金（2009-2008）;北京希望马拉松专项基金（LC2007852）

摘　　要：目的探讨MUM1／IRF4在滤泡性淋巴瘤（FL）中的表达情况及临床病理意义。方法对96例FL患者标本进行MUM1、CD10bcl－2、bcl－6、Ki－67免疫组织化学染色，并与患者的临床资料和病理学特征比较。结果MUMl在96例1FL中总的阳性率为59．2％（58／96），其中1～2级组阳性率为36．2％（19／51），3级组阳性率为86．4％（39／45）（χ2＝24．406，P〈0．001）。68．9％伴有弥漫成分的FL患者MUM1阳性（χ2＝－8．161，P=0．004）。MUM1和CD10的表达呈负相关，83．3％的CD10阴性病例表达MUM1（χ2＝－12．649，P〈0．001）。MUM1阳性者核分裂和Ki-67标记指数高于MUM1阴性者（t=－3．852、t=-4．610，P〈0．001）。结论MUM1可作为FL分型的标志物。MUM1阳性的FL可能为类似非生发中心B细胞分化特征的高度恶性淋巴瘤。Objective To clarify the MUM1/IRF4 expression in follicular lymphoma （FL） and its clinical and pathological significance. Methods Ninety-six cases FL were immunostained with MUM1, CDlc, bcl-2, bc1-6 and Ki-67 antibodies. The results were compared with their clinical and pathological features. Results The overall MUM1 expression rate in FL was 59.2 % （58/96）, including 36.2 % （19/51） grade 1 or 2 and 86.4 %（39/45） grade 3 cases （X2 =24.406, P 〈0.001）. 68.9 % cases with diffuse area were MUM1 positive （X2 =8.161, P =0.004）. MUM1 and CD10 expression had inverse correlation, 83.3 % CD10 negative cases were MUM1 positive （X2= 12.649, P 〈0.001）. The mitosis rate and Ki-67 label index were statistically higher in MUM1 positive cases than in negative cases （t = -3.852 ＆ -4.610, respectively, P 〈0.001）. Conclusion MUM1 can be used as a biomarker to divide FL into different malignancies. The MUM1 positive FL may be the feature of high grade non germinal center B cell malignant lymphoma.

关 键 词：淋巴瘤 滤泡型 MUM1/IFR4 免疫组织化学 

分 类 号：R733.1[医药卫生—肿瘤]